CA2694122A1 - Central administration of stable formulations of therapeutic agents for cns conditions - Google Patents

Central administration of stable formulations of therapeutic agents for cns conditions Download PDF

Info

Publication number
CA2694122A1
CA2694122A1 CA2694122A CA2694122A CA2694122A1 CA 2694122 A1 CA2694122 A1 CA 2694122A1 CA 2694122 A CA2694122 A CA 2694122A CA 2694122 A CA2694122 A CA 2694122A CA 2694122 A1 CA2694122 A1 CA 2694122A1
Authority
CA
Canada
Prior art keywords
therapeutic agent
cns
cns therapeutic
human
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2694122A
Other languages
English (en)
French (fr)
Inventor
Karen E. Stevens
Daniel J. Abrams
Tom Anchordoquy
Raymond Bunch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Colorado Colorado Springs
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2694122A1 publication Critical patent/CA2694122A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0085Brain, e.g. brain implants; Spinal cord
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/145Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2694122A 2007-07-25 2008-07-25 Central administration of stable formulations of therapeutic agents for cns conditions Abandoned CA2694122A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US96655407P 2007-07-25 2007-07-25
US60/966,554 2007-07-25
PCT/US2008/009109 WO2009014762A1 (en) 2007-07-25 2008-07-25 Central administration of stable formulations of therapeutic agents for cns conditions

Publications (1)

Publication Number Publication Date
CA2694122A1 true CA2694122A1 (en) 2009-01-29

Family

ID=40281688

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2694122A Abandoned CA2694122A1 (en) 2007-07-25 2008-07-25 Central administration of stable formulations of therapeutic agents for cns conditions

Country Status (4)

Country Link
EP (1) EP2180884A4 (de)
AU (1) AU2008279636A1 (de)
CA (1) CA2694122A1 (de)
WO (1) WO2009014762A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008095221A1 (en) 2007-02-07 2008-08-14 Gosforth Centre (Holdings) Pty Ltd Treatment of adhd
WO2009151741A1 (en) * 2008-04-01 2009-12-17 The Regents Of The University Of Colorado Methods and compositions for the intracerebroventricular administration of felbamate
EP2331088A4 (de) 2008-08-06 2011-10-12 Gosforth Ct Holdings Pty Ltd Zusammensetzungen und verfahren zur behandlung von psychiatrischen erkrankungen
US11511035B2 (en) 2016-07-28 2022-11-29 Cerebral Therapeutics, Inc. Implantable intraventricular sampling and infusion access device
US20190151239A1 (en) 2016-07-28 2019-05-23 Cerebral Therapeutics LLC Infusing drug solution directly into brain fluid
AU2018354181A1 (en) 2017-10-23 2020-03-12 Cerebral Therapeutics LLC High concentration valproic acid solutions for treating neurological disorders
EP3520803A1 (de) * 2018-01-31 2019-08-07 Zarodex Therapeutics Limited Neuartige verwendungen
TW202114655A (zh) 2019-08-14 2021-04-16 瑞士商辛鐵堤卡公司 左乙拉西坦(levetiracetam)之鞘內投藥
IL299827B1 (en) 2020-07-15 2026-04-01 Cerebral Therapeutics Inc A medical system that includes two access ports
US12102636B2 (en) * 2021-02-11 2024-10-01 Medtronic, Inc. Administration of antipsychotics
US12605537B2 (en) 2022-02-15 2026-04-21 Biogen Ma Inc. Implantable medical device for use with or having recording electrode

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5594190A (en) * 1989-06-02 1990-12-06 Ciba-Geigy Ag Intravenous solutions with a rapid onset of action
FR2716680B1 (fr) * 1994-02-25 1996-04-05 Adir Nouveaux dérivés de benzodioxane, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
US20050090548A1 (en) * 2003-10-23 2005-04-28 Medtronic, Inc. Intrathecal gabapentin for treatment of epilepsy
CA2605651C (en) * 2005-04-26 2013-10-08 Ambryx Biotechnology, Inc. Compositions and methods for treating or preventing overweight or obesity with zinc-charged protein fragments
US20070149466A1 (en) * 2005-07-07 2007-06-28 Michael Milburn Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders
JP2009523802A (ja) * 2006-01-17 2009-06-25 リージェンツ オブ ザ ユニバーシティー オブ コロラド Cns状態のための治療剤の安定製剤の中枢投与

Also Published As

Publication number Publication date
AU2008279636A1 (en) 2009-01-29
EP2180884A1 (de) 2010-05-05
WO2009014762A1 (en) 2009-01-29
EP2180884A4 (de) 2013-04-17

Similar Documents

Publication Publication Date Title
CA2694122A1 (en) Central administration of stable formulations of therapeutic agents for cns conditions
AU2007207606A1 (en) Central administration of stable formulations of therapeutic agents for CNS conditions
US6261582B1 (en) Surgical method and composition therefor
Bell et al. S‐adenosylmethionine blood levels in major depression: changes with drug treatment
US6599906B1 (en) Method of local anesthesia and analgesia
ES2307975T3 (es) Composiciones analgesicas que comprenden antagonistas del receptor de nmda y cloruro de benzalconio.
Allen et al. Time course and role of morphine dose and concentration in intrathecal granuloma formation in dogs: a combined magnetic resonance imaging and histopathology investigation
EP1727549A1 (de) Intranasale benzodiazepin-zusammensetzungen
US20140100183A1 (en) Central administration of stable formulations of therapeutic agents for cns conditions
US10076522B2 (en) Systems and methods for treating bacterial infection
KR20190035965A (ko) 연장된 지속 기간의 국소 마취제 제형
EP2273993A1 (de) Verfahren und zusammensetzungen zur intrazerebroventrikulären verabreichung von felbamat
Rodriguez-Navarro et al. Potentiation of local anesthetic activity of neosaxitoxin with bupivacaine or epinephrine: development of a long-acting pain blocker
Natalini et al. Analgesic and cardiopulmonary effects of epidural romifidine and morphine combination in horses
US9504666B2 (en) Chloroprocaine-based pharmaceutical composition for repeated intrathecal administration
Sauneuf et al. Clinical and EEG features of acute intrathecal baclofen overdose
CN101400335A (zh) 用于cns病症的治疗剂的稳定制剂的中枢给药
US11590105B2 (en) Intrathecal administration of levetiracetam
Hussain et al. Analgesic Effects of Pre-induction Low-dose Ketamine on Post-tonsillectomy Patients
Hydrochloride Bupivacaine Hydrochloride
Leuwer et al. Neuromuscular blocking agents and skeletal muscle relaxants

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20140725